Showing posts with label biotech. Show all posts
Showing posts with label biotech. Show all posts
Thursday, August 15, 2013
Tuesday, December 11, 2012
23andMe nabs billionaire Yuri Milner as investor, cuts price to $99
http://www.forbes.com/sites/matthewherper/2012/12/11/23andme-nabs-billionaire-yuri-milner-as-investor-cuts-price-to-99/
The reinvestment may be a sign, along with sale of DeCode Genetics to Amgen yesterday, in further renewed interest in the power of genetic technologies for the development of drugs and other medical interventions.
The reinvestment may be a sign, along with sale of DeCode Genetics to Amgen yesterday, in further renewed interest in the power of genetic technologies for the development of drugs and other medical interventions.
Monday, December 10, 2012
With DeCode Deal, Amgen Aims To Discover Drugs Like We Meant To In 1999
http://www.forbes.com/sites/matthewherper/2012/12/10/with-decode-deal-amgen-aims-to-discover-drugs-like-we-meant-to-1999/
In science, Stefansson says, “every question begets another question, so there is no final question.” Publishing a result doesn’t put the publisher behind, he argues. “The advantage is never going to come from being able to answer one question and sit on the answer, it is going to come from the ability answer the next questions. The advantage comes not from getting specific discoveries and sequestering them it is going to derive from our ability to continue to answer questions.”
In science, Stefansson says, “every question begets another question, so there is no final question.” Publishing a result doesn’t put the publisher behind, he argues. “The advantage is never going to come from being able to answer one question and sit on the answer, it is going to come from the ability answer the next questions. The advantage comes not from getting specific discoveries and sequestering them it is going to derive from our ability to continue to answer questions.”
Sunday, December 18, 2011
Recombinant Innovation - Drawing from oral histories, Hughes describes the origins, growth, and fall of the biotech pioneer Genentech.
Recombinant Innovation
Gerald Barnett
Drawing from oral histories, Hughes describes the origins, growth, and fall of the biotech pioneer Genentech.
http://www.sciencemag.org/content/334/6062/1497.full
Genentech The Beginnings of Biotech by Sally Smith Hughes University of Chicago Press, Chicago, 2011. 229 pp. $25, £16. ISBN 9780226359182. Synthesis.
E-mail: gerald.barnett@gmail.com
Genentech was one of the early and most successful companies formed in the biotech revolution. Sally Smith Hughes's Genentech chronicles a progression of events from Stanley Cohen and Herbert Boyer's invention of recombinant DNA in 1973 through the company's initial public offering in 1980—including the efforts to raise money and the race to prove the technology by making a commercially valuable product (such as insulin and human growth hormone). Drawing on oral histories, Hughes supplements her narrative with a wealth of archival material from the University of California (UC) and Genentech.
Gerald Barnett
Drawing from oral histories, Hughes describes the origins, growth, and fall of the biotech pioneer Genentech.
http://www.sciencemag.org/content/334/6062/1497.full
Genentech The Beginnings of Biotech by Sally Smith Hughes University of Chicago Press, Chicago, 2011. 229 pp. $25, £16. ISBN 9780226359182. Synthesis.
E-mail: gerald.barnett@gmail.com
Genentech was one of the early and most successful companies formed in the biotech revolution. Sally Smith Hughes's Genentech chronicles a progression of events from Stanley Cohen and Herbert Boyer's invention of recombinant DNA in 1973 through the company's initial public offering in 1980—including the efforts to raise money and the race to prove the technology by making a commercially valuable product (such as insulin and human growth hormone). Drawing on oral histories, Hughes supplements her narrative with a wealth of archival material from the University of California (UC) and Genentech.
Subscribe to:
Posts (Atom)